-
Signature
-
/s/ Lori Braender, as Attorney-In-Fact
-
Stock symbol
-
AQST
-
Transactions as of
-
Oct 15, 2025
-
Transactions value $
-
-$396,133
-
Form type
-
4
-
Date filed
-
10/17/2025, 02:01 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Jung Cassie |
Chief Operating Officer |
C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN |
/s/ Lori Braender, as Attorney-In-Fact |
2025-10-16 |
0001960154 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
AQST |
Common Stock |
Options Exercise |
$77.6K |
+25K |
+8.82% |
$3.10 |
308K |
Oct 15, 2025 |
Direct |
F1 |
| transaction |
AQST |
Common Stock |
Sale |
-$474K |
-67.6K |
-21.92% |
$7.01 |
241K |
Oct 15, 2025 |
Direct |
F2 |
| holding |
AQST |
Common Stock |
|
|
|
|
|
2K |
Oct 15, 2025 |
by spouse |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
AQST |
Non-Qualified Stock Option (right to buy) |
Options Exercise |
$0 |
-25K |
-100% |
$0.00 |
0 |
Oct 15, 2025 |
Common Stock |
25K |
$3.10 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Cassie Jung is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: